Creon DR 36,000 unit capsule UU 100S
Ended Awarded Last action
- Contract number
- SPE2DR26F6SU1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,635
Award facts
- Contract value 100% obligated
- $19,634.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $19,634.62, was awarded on February 4, 2026, to AmerisourceBergen Drug Corp (a subsidiary of Cencora, Inc.) for the supply of 36,000 units of Creon DR 100 capsules. The contract is firm fixed-price with a completion date of February 5, 2026, and represents a non-competitive set-aside award. The work will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is executed under the Defense Logistics Agency Troop Support Medical Indefinite Delivery Contract (valued at up to $999,999,999.00 through December 2026), which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally.
The Defense Logistics Agency funds this procurement as part of its medical supply chain operations supporting the Department of Defense and associated federal health systems. Creon (pancrelipase) is a digestive enzyme replacement therapy used to treat pancreatic insufficiency in patients with conditions such as cystic fibrosis and chronic pancreatitis. AmerisourceBergen's role as the prime vendor under the DLA's comprehensive pharmaceutical contract demonstrates its significant capabilities in efficiently delivering specialized pharmaceutical products required by military treatment facilities and other federal medical institutions. The contractor's established infrastructure and SAM.gov registration ensure compliance with federal procurement requirements.
Quick answers
Who was awarded contract SPE2DR26F6SU1?
SPE2DR26F6SU1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26F6SU1 worth?
The government has obligated $19,635 on SPE2DR26F6SU1.
Is contract SPE2DR26F6SU1 an order under another contract?
Yes. SPE2DR26F6SU1 is a delivery order under SPE2DR25D2108, an indefinite delivery contract.
Was contract SPE2DR26F6SU1 competed?
The extent of competition for SPE2DR26F6SU1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award